EU Guidelines On Justifying Phthalates In Medical Devices Applicable To Growing List Of Regulated Substances

 
• By Lauren Nardella

The European Commission’s Scientific Committee on Health, Environmental and Emerging Risks makes minor changes to its phthalates benefit-risk guidelines based on stakeholder feedback. The guidelines could be increasingly relevant given their applicability to other carcinogenic, mutagenic or reprotoxic (CMR) and endocrine-disrupting (ED) substances, lists that are bound to go on growing as the EU implements its Chemicals Strategy for Sustainability under the Green Deal.

• Source: Shutterstock

Stakeholders should bear in mind that updated European guidelines for assessing benefits versus risks of phthalates in medical devices are not just applicable to phthalates that have carcinogenic, mutagenic, toxic to reproduction or endocrine-disrupting properties, but can be used in evaluating other CMR/ED substances in medical devices as well.

And there are quite a few

Intertek Group plc, a British multinational provider of assurance, testing, inspection and certification services, said in a 2020

More from Regulation

More from Policy & Regulation